Vigilant Capital Management’s Elanco Animal Health ELAN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
$11K Sell
1,063
-315
-23% -$2.92K ﹤0.01% 392
2023
Q1
$13K Hold
1,378
﹤0.01% 373
2022
Q4
$17K Sell
1,378
-610
-31% -$7.6K ﹤0.01% 358
2022
Q3
$25K Hold
1,988
﹤0.01% 359
2022
Q2
$39K Hold
1,988
﹤0.01% 301
2022
Q1
$52K Hold
1,988
﹤0.01% 290
2021
Q4
$56K Hold
1,988
﹤0.01% 302
2021
Q3
$63K Hold
1,988
0.01% 240
2021
Q2
$69K Hold
1,988
0.01% 234
2021
Q1
$59K Hold
1,988
0.01% 230
2020
Q4
$61K Hold
1,988
0.01% 210
2020
Q3
$56K Hold
1,988
0.01% 212
2020
Q2
$43K Hold
1,988
0.01% 215
2020
Q1
$45K Hold
1,988
0.01% 207
2019
Q4
$59K Hold
1,988
0.01% 265
2019
Q3
$53K Hold
1,988
0.01% 244
2019
Q2
$67K Hold
1,988
0.01% 213
2019
Q1
$64K Buy
+1,988
New +$61.2K 0.01% 222

Other funds holding ELAN

Vigilant Capital Management's ELAN Position: Q2 2023 in Review

Vigilant Capital Management reduced its Elanco Animal Health (ELAN) stake by 23% in Q2 2023, selling an estimated $2.92K and leaving 1,063 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #392.

Vigilant Capital Management first reported a position in ELAN in Q1 2019 and has held it in 18 quarters since. The position peaked at $69K in Q2 2021. 351 funds tracked by Wall St. Rank hold ELAN as of Q2 2023.

  • Vigilant Capital Management held 1,063 shares of Elanco Animal Health worth $11K as of Q2 2023.
  • Vigilant Capital Management sold 315 Elanco Animal Health shares in Q2 2023, an estimated $2.92K.
  • Elanco Animal Health made up ﹤0.01% of Vigilant Capital Management's portfolio in Q2 2023, its #392 holding.
  • Vigilant Capital Management first reported a position in Elanco Animal Health in Q1 2019 and has held it in 18 quarters since.
  • Vigilant Capital Management's Elanco Animal Health position peaked at $69K in Q2 2021.
  • 351 funds tracked by Wall St. Rank held Elanco Animal Health as of Q2 2023.

Based on Vigilant Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.